Bio-Path Holdings - Volume dana dhuwit perusahaan BPTH

Simbol resmi perusahaan biopathholdings.com (BPTH)

Operating cash flow on the GURU.Markets portal demonstrates the potential of Bio-Path Holdings (BPTH) antisense agents against leukemia, whose patent protection promises high margins. The current level of this metric is 0.00. Growing liquidity supports a unique liposomal drug delivery system into tumors. However, risks of testing delays and equity dilution due to frequent secondary offerings create significant uncertainty for investors.

Bio-Path Holdings Inc. - Gunggung dana dhuwit perusahaan BPTH (periode 04.07.2022 - 01.03.2025)

Rincian metrik keuangan lan pasar Bio-Path Holdings, Inc. (BPTH)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:BPTH Bio-Path Holdings Inc.
Sampel barang biopathholdings.com

This metric measures the total volume of liquid assets, determining the issuer's ability to cover operating expenses without incurring external debt. By analyzing the cash balance chart, an investor can promptly identify the risk of a liquidity gap. This trend is driven by inflows from equity offerings and operating activities minus development costs. For Bio-Path Holdings (BPTH), this is critical when funding BP1001 trials and supporting the nucleic acid delivery platform. A sufficient cash reserve guarantees the completion of research before securing new grants.